Diabetes accelerates retinal ganglion cell dysfunction in mice lacking sigma receptor 1

Yonju Ha,1,2 Alan Saul,2,3 Amany Tawfik,1,2 Eric P. Zorrilla,4 Vadivel Ganapathy,2,5 Sylvia B. Smith1,2,3

1Department of Cellular Biology and Anatomy, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA; 2Vision Discovery Institute, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA; 3Department of Ophthalmology, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA; 4Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA

Purpose: Sigma receptor 1 (σR1) is a non-opioid transmembrane protein that may act as a molecular chaperone at the endoplasmic reticulum–mitochondrial membrane. Ligands for σR1, such as (+)-pentazocine [(+)-PTZ], confer marked retinal neuroprotection in vivo and in vitro. Recently we analyzed the retinal phenotype of mice lacking σR1 (σR1 KO) and observed normal retinal morphology and function in young mice (5–30 weeks) but diminished negative scotopic threshold responses (nSTRs), retinal ganglion cell (RGC) loss, and disruption of optic nerve axons consistent with inner retinal dysfunction by 1 year. These data led us to test the hypothesis that σR1 may be critical in forestalling chronic retinal stress; diabetes was used as the model of chronic stress.

Methods: To determine whether σR1 is required for (+)-PTZ neuroprotective effects, primary RGCs isolated from wild-type (WT) and σR1 KO mice were exposed to xanthine–xanthine oxidase (10 µM:2 mU/ml) to induce oxidative stress in the presence or absence of (+)-PTZ. Cell death was evaluated by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis. To assess effects of chronic stress on RGC function, diabetes was induced in 3-week C57BL/6 (WT) and σR1 KO mice, using streptozotocin to yield four groups: WT nondiabetic (WT non-DB), WT diabetic (WT-DB), σR1 KO non-DB, and σR1 KO-DB. After 12 weeks of diabetes, when mice were 15-weeks old, intraocular pressure (IOP) was recorded, electrophysiologic testing was performed (including detection of nSTRs), and the number of RGCs was counted in retinal histological sections.

Results: In vitro studies showed that (+)-PTZ could not prevent oxidative stress-induced death of RGCs harvested from σR1 KO mice but afforded robust protection against death of RGCs harvested from WT mice. In the studies of chronic stress induced by diabetes, the IOP measured in the four mouse groups was within the normal range; however, there was a significant increase in the IOP of σR1 KO-DB mice (16±0.5 mmHg) compared to the other groups tested (σR1 KO non-DB, WT non-DB, WT-DB: ~12±0.6 mmHg). Regarding electrophysiologic testing, the nSTRs of σR1 KO non-DB mice were similar to WT non-DB mice at 15 weeks; however, they were significantly lower in σR1 KO-DB mice (5±1 μV) compared to the other groups, including, notably, σR1 KO-nonDB (12±2 μV). As expected, the number of RGCs in σR1 KO non-DB mice was similar to WT non-DB mice at 15 weeks, but under chronic stress of diabetes there were fewer RGCs in retinas of σR1 KO-DB mice.

Conclusions: This is the first report showing unequivocally that the neuroprotective effects of (+)-PTZ require σR1. σR1 KO mice show normal retinal structure and function at young ages; however, when subjected to the chronic stress of diabetes, there is an acceleration of retinal functional deficits in σR1 KO mice such that ganglion cell dysfunction is observed at a much earlier age than nondiabetic σR1 KO mice. The data support the hypothesis that σR1 plays a key role in modulating retinal stress and may be an important target for retinal disease.

Sigma receptor 1 (σR1) is a ~27-kDa transmembrane protein originally described as an opioid receptor [1] but later identified as a unique pharmacological receptor [2]. It shares no sequence homology with any other mammalian protein. The endogenous function of σR1 is not certain; owing to its location at the endoplasmic reticulum (ER)–mitochondrial membrane, it may play an important role as a chaperone modulating ER stress [3,4]. Beneficial effects of putative σR1 ligands, such as decreased pain, enhanced memory, and neuroprotection, suggest that σR1 could be an important therapeutic target in several diseases [3], including ocular and retinal diseases. σR1 is expressed in multiple ocular tissues, such as lacrimal gland [5], cornea, iris–ciliary body, lens, and retina [6,7]. In retina it is expressed abundantly in the ganglion cell and inner nuclear layers [6,8-10], in photoreceptor [6,9] and retinal pigment epithelium (RPE) cells [6,11], and the optic nerve [6,10]. In isolated retinal Müller
and retinal ganglion cells (RGCs), σR1 has been detected on ER and nuclear membranes [12,13].

Robust retinal neuroprotective effects of σR1 ligands have been reported by several laboratories; these effects include protection against RGC apoptotic death in vitro using the putative σR1 ligands (+)-pentazocine [(+)-PTZ] and SKF-10,047 [14-18]. Marked preservation of retina was observed in vivo in Ins2Akita diabetic mice treated for several weeks with (+)-PTZ [19]. Given its role in neuroprotection and cell survival, its abundant expression in eye, and its putative function as a molecular chaperone, we asked recently whether σR1 is critical for ocular development and/or maintenance of normal ocular structure/function. The availability of genetically manipulated mice lacking σR1 (σR1 KO mice) [20] offered a tool to address this question. Functional, morphologic, and cell biologic tools were used to examine comprehensively the ocular phenotype in σR1 KO versus wild-type (WT) mice over a 1-year period [21]. The data showed that the anterior segments of the eye (cornea, lens, ciliary body–iris) were histologically normal in σR1 KO mice and intraocular pressure (IOP) was within normal limits at all ages examined. In the retina, however, there were functional and morphologic changes observed, albeit not until the mice were several months old. For example, electrophysiological changes in σR1 KO mice, including significantly decreased electroretinogram (ERG) b-wave amplitudes and diminished negative scotopic threshold responses (nSTRs), emerged at approximately 12 months of age consistent with a late-onset inner retinal dysfunction. Morphologic analyses revealed significantly fewer cells in the ganglion cell layer, but again not until the mice were many months of age. Ultrastructural studies provided evidence of disrupted optic nerve axons, including accumulation of organelles (swollen mitochondria) and glial cell apoptosis, in 33-week-old mice.

While σR1 is not essential for normal ocular/retinal development, the reviewed results suggest it may play a critical role in forestalling retinal cellular stress. Recently, Guo and colleagues investigated this role in an acute injury model [10]. They performed intraorbital optic nerve crush in σR1 KO mice and determined that the number of surviving cells in the ganglion cell layer of σR1 KO was significantly decreased (18.5%) compared to WT mice subjected to the same injury. Their data strongly support the notion that lack of σR1 increases susceptibility to acute retinal injury. The effects of chronic stress to the retina in the absence of σR1, however, have not been explored. In the present study we asked whether the late-onset RGC death reported for σR1 KO mice, which is not observed until the mice are ~1 year [21], would be accelerated under the chronic stress of diabetes.

Diabetes represents one of the most clinically relevant forms of chronic stress encountered by retina; it is the leading cause of new cases of blindness among adults aged 20–44 years, causing from ~12,000 to 24,000 new cases of blindness yearly [22]. The myriad consequences of this disease on retina include neuronal cell loss and vascular complications [23]. In the present study we induced diabetes in σR1 KO and WT mice and investigated IOP, electrophysiologic function, and RGC viability in the animals after 12 weeks of diabetes. Our data show that the chronic stress of diabetes accelerates RGC dysfunction in the σR1 KO mice and suggest that σR1 is an important player in managing retinal stress.

METHODS

**Animals:** The generation of σR1 KO mice, establishment of the colony in our animal facility, and details about genotyping have been described [21]. Briefly, the heterozygous mice were obtained from Mutant Mouse Resource Regional Center and implanted into female C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) at The Scripps Research Institute. The generation of σR1 KO mice, establishment of the colony in our animal facility, and details about genotyping have been described [21]. Briefly the genotyping uses polymerase chain reaction (PCR) to determine the presence of σR1 using three primers (a) 5′-TCT GAG TAC GT G CTG CTC TTC G-3′, (b) 5′-ATA AAC CCT CTT GCA GTT GCA TC-3′, (c) 5′-GAA ACT GCC GT G TTC TGC TGT TTC C-3′ the conditions of which were: 30 cycles at 94 °C (15 s), 55 °C (30 s) and 72 °C (40 s). Founder heterozygous mice were transferred to the animal facility at Georgia Health Sciences University to allow us to establish our colony. For the first set of experiments in which RGCs were isolated, 78 neonatal mice (σR1 KO and WT) were used as described below. In the studies examining the effects of diabetes, 40 mice were used to generate four mouse groups: (1) WT nondiabetic (WT non-DB), (2) WT diabetic (WT-DB), (3) σR1 KO non-DB, and (4) σR1 KO-DB. Mice were made diabetic at 3 weeks of age, using streptozotocin per our method [24]. Briefly, they received an intraperitoneal injection of 75 mg/kg STZ dissolved in sodium citrate buffer (0.01 M, pH 4.5) on three successive days. Mice were maintained for 12 weeks after which they were weighed, subjected to functional testing as described below, and blood glucose and insulin levels measured. Mice were not administered insulin at any time during the experiments and typically do not survive beyond approximately 18–20 weeks of diabetes, which was the rationale for ending the experiment after 12 weeks diabetes duration (when mice were 15 weeks of age). Mice were maintained for 12 weeks after which they were weighed, subjected to functional testing as described below.
Blood was collected from the cardiac ventricle at the time the animals were euthanized; blood samples were used immediately to determine glucose and insulin levels (described below). Mice were rapidly euthanized by carbon dioxide asphyxiation/cervical dislocation per our approved protocol. Eyes were harvested at the termination of the experiment and prepared for cryosectioning per our method in immunohistochemical studies [19,21]. Briefly, the eyes were oriented in Optimal Cutting Temperature compound (Electron Microscopy Sciences, Hatfield, PA), frozen slowly in liquid nitrogen and then cryosectioned (10 um thickness). The sections were placed on Superfrost Slides (Fisher Scientific Corp., Pittsburgh, PA) and stored at −80 °C until used. Maintenance of animals adhered to the Georgia Health Sciences University (GHSU) institutional guidelines for the humane treatment of animals following our IACUC approved protocol and to the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthamlic and Vision Research.

Analysis of (+)-pentazocine as a neuroprotective ligand via sigma receptor 1: Primary RGCs were isolated from mouse pups (WT and σR1 KO) at postnatal day 3. Immunopanning procedures and verification of purity of the cells have been described in detail [13,15]. Briefly, retinas were subjected to a two-step process using anti-macrophage antiserum to remove the macrophages and microglial cells; the non-adherent cells were then incubated in with anti-mouse Thy-1.2 antibody to isolate the ganglion cells. The purity of the cells has been verified to show that they are positive for neuronal markers and negative for glial and RPE markers. Cells were seeded at a density of 2.3×10^4 cells per well and were incubated at 37 °C in media that was changed every 2 days. Since these are primary cultures of RGCs, they are not amenable to passage and they do not proliferate; they do, however, extend neurite processes, evincing characteristics of neurons. Differential interference contrast (DIC) images were captured using a Nikon ECLIPSE TS100 inverted microscope (Nikon, Sendai, Japan) equipped with a Moticam 2300 camera (Motic Instruments Inc., Richmond, British Columbia, Canada) and Motic Images Plus 2.0 software (Motic Instruments Inc.). To determine whether (+)-PTZ, a putative σR1 ligand, would afford protection in the absence of σR1, cells were exposed to xanthine–xanthine oxidase (X: XO) 10 μM:2 mU/ml in the presence/absence of 3 μM (+)-PTZ (Sigma-Aldrich Corp, St. Louis, MO) for 18 h. The number of cells undergoing apoptosis, as detected by the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, was quantified as described previously [13,15]. Exposure to X: XO is a well known method for generating superoxide and hydrogen peroxide in a molar ratio of approximately 1:3 [25]. The concentration and duration of exposure to X: XO as well as the concentration of (+)-PTZ used in this study were based on extensive previous studies showing that this level of oxidative stress significantly increases cell death and that 3 μM (+)-PTZ can significantly inhibit cell death [13,15]. Essentially, the present experiments recapitulated those studies in cells that have σR1 (RGCs from WT) versus those that lack this putative target for (+)-PTZ (RGCs from σR1 KO).

Measurement of intraocular pressure and retinal function: IOP was measured by placing the probe of a handheld iCare rebound tonometer (Icare Finland Oy, Espoo, Finland) on the cornea [21]. Negative scotopic threshold recordings (nSTRs) were performed under isoflurane anesthesia in diabetic and nondiabetic mice. The nSTRs were obtained with 5-ms flashes of a blue (470 nm) light emitting diode, made dimmer with neutral-density filters and defocusing. Just above threshold, a late negative potential develops at ∼200 ms after the flash; this is the negative (n)STR [21]. Daytime measurements were obtained at approximately 12:00 noon and nighttime measurements at approximately 12:00 midnight. Mouse weights were determined along with blood glucose, using a glucometer (Abbot Diabetes Care, Alameda, CA), and blood insulin, measured using the Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem Inc., Downers Grove, IL) per the manufacturers’ instructions and blood insulin was measured using the Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem Inc., Downers Grove, IL) in a spectrophotometric assay.

Quantitative immunohistochemical analyses of cells in the ganglion cell layer: Brn3a is a well characterized marker for RGCs [26], and cleaved caspase-3 is a marker for apoptosis [21]. Immunohistochemical detection methods were used to determine the number of RGCs in retinal cryosections, using a goat polyclonal antibody against Brn-3a (1:100; Santa Cruz Corp., Santa Cruz, CA) followed by incubation with AlexaFluor-488-conjugated donkey anti-goat immunoglobulin (IgG) secondary antibody (1:1,000; Invitrogen, Carlsbad, CA). To detect apoptotic cells, sections were incubated with a rabbit polyclonal antibody against cleaved caspase-3 (1:250; Cell Signaling Technology, Beverly, MA). For detection of immunopositive signals, retinal sections were incubated with AlexaFluor-555-conjugated donkey anti-rabbit IgG secondary antibody (1:1,000; Invitrogen). Coverslips were mounted on slides using fluorescein with 4,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich Corp) to label nuclei and viewed by epifluorescence, using a Zeiss Axioplan-2 microscope (Carl Zeiss, Oberkochen, Germany) equipped with the AxioVision program (version 4.6.3) and an high resolution microscopy (HRM) camera. Brn3a-positive cells were counted, and data
were expressed as the number of cells per 100 µm retinal length. Slides incubated with only the secondary antibody were used as negative control; there was no labeling detected in the absence of the primary antibody (data not shown).

Statistical analysis: The data for ERG analysis and quantification of RGCs in retinal sections were analyzed by the Student t test. One-way ANOVA was used to determine whether there were significant differences in the number of TUNEL-positive cultured RGCs, bodyweight, blood glucose levels, insulin levels, and IOP. Tukey’s paired comparison test was the post hoc statistical test. Statistical analysis was conducted using the GraphPad Prism analytical program (GraphPad Software, Inc., San Diego, CA). A p value of <0.05 was considered significant.

RESULTS

Sigma receptor 1 is required for (+)-pentazocine neuroprotection against oxidative-induced stress: There have been several studies suggesting that (+)-PTZ is protective against neuronal cell death; however, it is not known whether (+)-PTZ requires σR1 to confer neuroprotection or whether it might act through some other receptor. The availability of σR1 KO mice allowed this question to be addressed. During the early postnatal period, retinal function and structure appear normal in σR1 KO mice [21], permitting isolation and culture of RGCs from these mutant mice. RGCs isolated from WT and σR1 KO mice were used to examine whether (+)-PTZ would afford neuroprotection in the absence of σR1, its putative target. RGCs were isolated from WT and σR1 KO neonatal mice and allowed to grow in culture media for 72 h, over which time the extension of neurite processes was examined. Differential interference contrast microscopy (DIC) microscopy revealed neurite development in RGCs harvested from σR1 KO mice as well as WT (Figure 1A). The dendritic arborizations and axonal projections were comparable between the two mouse groups. When cells were treated with X:OX, there was a significant increase in the number of TUNEL-positive RGCs in WT and σR1 KO RGCs; approximately 20%–25% of RGCs died within 18 h incubation with X:OX (Figure 1B). Thus, RGCs of σR1 KO mouse are susceptible to acute oxidative stress in a manner similar to WT. When the X:OX-exposed cells harvested from WT mice were co-treated with (+)-PTZ, there was a marked decrease in cell death, which is consistent with previous reports [13]. When RGCs harvested from σR1 KO mice were exposed to X:OX in the presence of (+)-PTZ, however, there was no protection against cell death. There was no significant difference in cell death observed in the X:OX treated group compared to the X:OX (+)-PTZ group. From these experiments we conclude that (+)-PTZ mediates neuroprotection by interacting with σR1 and that σR1 is obligatory for (+)-PTZ to be neuroprotective against RGC death.

Bodyweight, blood glucose, and insulin levels in diabetic mice versus controls: To determine whether in vivo chronic stress, in the form of diabetes, altered retinal structure and function in σR1 KO mice and in particular accelerated disruption of the retina, streptozotocin was administered to WT and σR1 KO mice. Bodyweight was determined before the streptozotocin injection and again at the termination of the experiment. Blood glucose levels and insulin levels were determined at the termination of the experiment. There were no differences in the weights of mice before induction of diabetes in any of the mouse groups analyzed (Figure 2A). After 12 weeks of diabetes, WT-DB and σR1 KO-DB mice weighed significantly less than WT non-DB and σR1 KO non-DB mice (Figure 2B). Blood glucose levels were elevated significantly in the WT-DB and σR1 KO-DB mice compared to their respective nondiabetic controls (Figure 2C); blood insulin levels were markedly reduced in the WT-DB and σR1 KO-DB mice (Figure 2D). There was a trend toward higher blood glucose levels and lower insulin levels in the σR1 KO-DB versus WT-DB, although the data did not reach statistical significance.

Increased intraocular pressure in diabetic σR1 KO mice: In our initial characterization of the retinal phenotype of σR1 KO mice, we measured IOP but did not observe any differences in this parameter over the 1-year period studied [21]—that is, lack of σR1 alone does not increase IOP. We wanted to investigate whether the additional stress of diabetes would alter IOP in the absence of σR1. IOP was examined after 10–12 weeks duration of diabetes. Diurnal variations in IOP have been reported [27]. The IOP measured for all animals was within the range of 10–20 mmHg, which is within normal limits. It is noteworthy that although within the normal range, the IOP in σR1 KO-DB mice was significantly higher than for any other mouse group studied. It was significantly higher than σR1 KO non-DB during the day (15.0±0.5 versus 13.25±0.46 mmHg, respectively, Figure 3A) as well as at night (16.2±0.5 mmHg versus 12.35±0.6, respectively, Figure 3B), in addition to being higher than WT non-DB and WT-DB mice at night. These data suggest that while diabetes itself is insufficient to increase IOP, it tends to increase IOP when σR1 is absent.

Decreased scotopic threshold responses in diabetic σR1 KO mice: STRs are the most sensitive ERG responses observable with dim stimuli in the dark-adapted state and are a reflection of RGC health [28,29]. They are obtained with 5 ms flashes of a blue (470 nm) light-emitting diode, made dimmer with
neutral density filters and defocusing. Just above threshold, a late negative potential develops at approximately 200 ms after the flash; this is the nSTR. One-year-old $\sigma R1$ KO mice have diminished nSTRs compared to WT mice \cite{21}, reflecting late-onset inner retinal dysfunction. In the present study, nSTRs were recorded in mice after 12 weeks of diabetes (~15 weeks of age). While there was no significant difference between nSTRs of $\sigma R1$ KO non-DB (12±2 µV) versus WT non-DB (14±2 µV) at this age (Figure 4), there was a significant reduction in nSTRs in the $\sigma R1$ KO-DB mice (5±1 µV). There was a significant reduction also in nSTRs of the $\sigma R1$ KO-DB mice compared to WT-DB mice (10±2 µV). These data suggest that the decline in RGC function characteristic of 1-year-old $\sigma R1$ KO mice is differentially accelerated by diabetes in the $\sigma R1$ null mutants.

**Assessment of retinal ganglion cells in diabetic $\sigma R1$ KO mice:**
RGC loss has been reported in retinas of $\sigma R1$ KO mice but only in mice of advanced age (~1 year); the numbers of RGCs in the 5 and 18 week $\sigma R1$ KO mice were not significantly different from age-matched WT mice \cite{21}. To determine whether diabetes accelerated the loss of RGCs in the absence of $\sigma R1$, immunohistochemical methods were used to label the retina of WT and $\sigma R1$ KO mice.
these cells in retinal cryosections (Figure 5A); the Brn3a-positive cells were then counted and expressed as number of cells in the ganglion cell layer (Figure 5B). There are several important observations from the data. There were significantly fewer RGCs in σR1 KO-DB mice compared with WT mice. That is, there is a marked decrease in the number of RGCs when diabetes occurs in the absence of σR1. Additionally, there were significantly fewer RGCs in σR1 KO-DB compared to σR1 (non-DB) as well as in the WT-DB compared to WT (non-DB) mice. The difference in the two deltas (WT group–DB versus non-DB compared to σR1 KO–DB versus nondiabetic) did not reach statistical significance. It is likely that frank dysfunction of the ganglion cells as measured in the electrophysiologic studies precedes measureable loss of the cells. We investigated also whether cells were undergoing apoptosis as evidenced by expression of cleaved caspase-3. It is clear that in both the σR1 KO-DB and the WT-DB mice there are more caspase-3-positive cells (Figure 5C), whereas caspase-3-positive cells were rarely observed in the WT or the σR1 KO mice at the age studied.

---

Figure 2. Bodyweight, blood glucose and insulin levels. Wild-type and σR1 KO mice were made diabetic using streptozotocin (STZ) at 3 weeks and the bodyweights and insulin levels determined from blood samples harvested at euthanasia. A: Bodyweights are provided for mice before STZ injection; B: Bodyweights are provided for mice at the termination of the experiment (12 weeks following STZ injection); C: Blood glucose levels are provided for mice 12 weeks following STZ injection; and D: Insulin levels are provided for mice 12 weeks following STZ injection. For these studies, 10 mice were tested per group (n=10). The data were significant as shown by the asterisk representing statistical analysis. (The asterisks denote between which groups there are significant statistical differences: *, p<0.05; **, p<0.01; ***, p<0.001).

Figure 3. Intraocular pressure. Intraocular pressure (IOP) was measured in wild-type, non-diabetic (WT-DB), Wild-type-diabetic (WT-DB), σR1 knockout non-diabetic (σR1 KO non-DB), and σR1 knockout diabetic (σR1 KO-DB) mice during the day (A) and night (B) after 12 weeks of diabetes. Data represent averaged values for the mice in the four groups (n=10 mice tested per group; the asterisks denote between which groups there are significant statistical differences: *, p<0.05; **, p<0.01; ***, p<0.001).
DISCUSSION

There were two major findings of the present study. The first was that the neuroprotective functions of (+)-PTZ are mediated via σR1, and the second was that in the absence of σR1, chronic stress accelerates RGC dysfunction.

Regarding the first finding, we took advantage of the observation that the absence of σR1 does not hinder normal retinal development [21] to investigate whether the previously reported neuroprotective effects of (+)-PTZ are mediated via σR1 versus another mechanism (e.g., a different receptor). While (+)-PTZ is considered a highly specific ligand for σR1 with an affinity in the nanomolar range (0.0046 µM [K_d]) [30], it has not been demonstrated unequivocally that (+)-PTZ mediates neuroprotection via σR1. Moreover, there have been reports of alternative targets for (+)-PTZ [31]. Thus, we designed an experiment to examine this question specifically in ganglion cells, the neuron that is particularly vulnerable in diabetic retinopathy [23]. By isolating ganglion cells from WT mice and from σR1 KO mice, we had a neuronal population that either did or did not contain σR1. The cells could be manipulated using a known stressor and we had clear endpoints (neurite processes, TUNEL positivity) that could be analyzed in a straightforward manner to inform whether (+)-PTZ afforded protection. RGCs were isolated following a well established immunopanning procedure from neonatal WT and σR1 KO mice; they were cultured under oxidative stress conditions with or without (+)-PTZ. The data showed that RGCs from σR1 KO mice succumbed to oxidative stress in a manner similar to those harvested from WT; however, unlike WT-treated cells, (+)-PTZ did not prevent death in cells isolated from σR1 KO mice. That is, (+)-PTZ did not protect against oxidative stress in cells lacking σR1. These findings provide compelling evidence that neuroprotective effects of (+)-PTZ are obligatorily dependent on σR1. The rationale for inducing neuronal death using oxidative stress is that oxidative stress (the overproduction of reactive oxygen species) has been measured indirectly in patients. Data suggest that reactive oxygen species levels are related to the severity of diabetic complications, including diabetic retinopathy [32-35]. It is noteworthy also that xanthine oxidase is increased...
Figure 5. Assessment of retinal ganglion cells (RGCs) in σR1 knockout (σR1-KO) and wild-type (WT) diabetic (DB) and non-diabetic mice (non-DB). Retinal cryosections were prepared from WT (non-DB), WT-DB, σR1 KO (non-DB), and σR1 KO–DB mice after 12 weeks of diabetes and subjected to immunohistochemistry. A: RGCs were labeled with Brn3a (green fluorescence) and nuclei were labeled with DAPI (blue). B: The numbers of Brn3a positive cells were counted and expressed per unit length of retina. C: Red and blue fluorescent signals reflect cleaved caspase-3 and DAPI staining of nuclei, respectively. The calibration bar in panels A and C=20 μm. Statistical differences between groups is denoted with an asterisk (*, p<0.05).
in type 1 diabetes [36]. As an extension of the in vitro studies reported here, future studies using σR1 KO mice could be performed in which a known retinal stressor is used to induce retinopathy in the presence/absence of (+)-PTZ to validate the findings we have obtained using the isolated cell approach.

Regarding the second finding of accelerated RGC dysfunction under chronic stress, σR1 is an abundantly expressed protein whose endogenous role in cells has been elusive. The present study examined the potential role of σR1 as a stress modulator in retina. Earlier studies provided compelling evidence that ligands for σR1 afford robust retinal neuroprotection. This has been demonstrated in vivo and in vitro in several independent laboratories. For example, Techedre and colleagues showed that the σR1 ligand SKF-10,047 could protect against RGC death by regulating intracellular calcium as well regulating expression of key apoptosis genes [37]. Bucolo and coworkers demonstrated that pretreatment with PRE-084, a selective σR1 agonist, increased viability of RPE cells and decreased DNA damage induced by oxidative insult [16]. Our laboratory has demonstrated protective effects of (+)-PTZ against oxidative and excitotoxic RGC death in vitro [13-15] and RGC death associated with diabetes in vivo [19].

Collectively, these findings suggest an important neuroprotective role of σR1 in retina. Interestingly, recent comprehensive studies of the retinal structure and function of σR1 KO mice demonstrate that σR1 is not required for normal retinal development [10,21]. Indeed, while σR1 KO mice demonstrate a late-onset retinal degeneration characterized by loss of RGCs, ultrastructural alterations of the optic nerve, and diminished ERG (nSTRs), the phenotype is not observed until the mice are nearly 1 year of age [21]. These observations led us and others to speculate that σR1 may play a role in modulating stress in the retina. Mavlyutov and colleagues investigated this using optic nerve crush in WT and σR1 KO mice to determine whether lack of σR1 rendered animals more susceptible to acute injury. Their data showed that 7 days after the crush, WT mice retained ~90% of their optic nerve axons while σR1 KO mice retained only ~70% [10]. They concluded that σR1 delays crush-induced RGC degeneration and that RGC death increases under acute injury in the absence of σR1.

In the current work, we examined the role of σR1 under chronic retinal stress in the form of diabetes. Diabetes was induced in WT mice and those lacking σR1 by injecting streptozotocin at 3 weeks of age. Eyes were evaluated 12 weeks post onset of diabetes when mice were 15 weeks of age. When σR1 KO non-DB mice were analyzed at this age, no functional deficits or structural alterations were observed, confirming earlier findings [21]. However, rendering the σR1 KO mice diabetic accelerated retinal dysfunction. Retinas were examined functionally by assessing IOP and nSTRs. σR1 KO-DB mice had IOPs that were significantly elevated at night compared to σR1 KO non-DB as well as to WT non-DB and WT-DB mice. The levels detected were ~15 mmHg, which is within the normal range; nevertheless, the elevation in σR1 KO-DB was significantly greater than in the other mouse groups examined. Whether σR1 plays a role in modulating IOP would be a fruitful area for further study. For example, it would be interesting to explore other chronic stressors in σR1 KO mice for their propensity to elevate IOP. Of note, Bucolo reported that topical σR1 agonists lower IOP in a rabbit model [38].

The other functional test performed was measurement of nSTRs; our data showed a marked decrease in nSTRs of the σR1 KO-DB mice compared to the other mice in the study. The nSTRs ranged between 9 and 13 µV for WT non-DB, WT-DB, and σR1 KO non-DB mice compared to ~5 µV in the σR1 KO-DB mice. The nSTR is a highly sensitive test for RGC activity; thus, these data provide strong evidence that σR1 modulates RGC function under chronic stress. As is the case with acute stress [10], chronic stress can accelerate RGC dysfunction in the absence of σR1. Accompanying the decreased RGC function was a decrease in the numbers of Brn3a-positive cells detected in the ganglion cell layer of σR1 KO-DB mice compared with WT mice. Our data clearly show that there is a much earlier loss of RGCs and evidence of inner retinal dysfunction in σR1 KO-DB mice compared with WT mice; this supports the role of σR1 in forestalling retinal stress. There is a decrease in the number of RGCs in σR1 KO-DB compared to σR1 (nondiabetic), although the decrease is similar to the decrease in cell number between WT and WT-DB. It appears that cell loss as an endpoint is not as severe an indicator as the nSTR and IOP changes we observed.

In summary, the in vivo data comparing diabetic versus nondiabetic σR1 KO mice have allowed us to investigate the role of chronic stress on retinal function in the absence of σR1. The acceleration of ganglion cell dysfunction during chronic diabetic stress coupled with the late onset inner retinal dysfunction of nondiabetic σR1 KO mice underscores the role of this protein as a stress modulator. These data complement the findings of the Guo laboratory [10] showing the importance of σR1 in an acute injury model. Collectively, the findings set the stage to determine the mechanism by which σR1 mediates neuroprotection in retina.
ACKNOWLEDGMENTS

We thank Ms. Amber Still for her assistance in electrophysiological testing of the mice, Mr. Cory Williams for maintaining the mouse colony and Ms. Penny Roon for expert technical assistance in preparing retinal cryosections for the immunohistochemical studies. This work was supported by NIH R01 EY014560 and by the GHSU Vision Discovery Institute. Portions of this work have been presented at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).

REFERENCES

1. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197:517-32. [PMID: 945347].

2. Quirion R, Bowen WD, Izhak Y, Junien JL, Musacchio JM, Rothman RB, Su TP, Tam SW, Taylor DP. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992; 13:85-6. [PMID: 1315463].

3. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007; 131:596-610. [PMID: 17981125].

4. Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci 2010; 31:557-66. [PMID: 20869780].

5. Schoenwald RD, Barf knecht CF, Xia E, Newton RE. The presence of sigma-receptors in the lacrimal gland. J Ocul Pharmacol 1993; 9:125-39. [PMID: 8345285].

6. Ola MS, Moore PM, El-Sherbeny A, Roon P, Agarwal N, Sarthy VP, Casellas P, Ganapathy V, Smith SB. Expression pattern of sigma receptor 1 mRNA and protein in mammalian retina. Brain Res Mol Brain Res 2001; 95:86-95. [PMID: 11687279].

7. Bucolo C, Campana G, Di Toro R, Cacciaguerri S, Spampinato S. Sigma 1 recognition sites in rabbit iris-ciliary body: topical sigma 1-site agonists lower intraocular pressure. J Pharmacol Exp Ther 1999; 289:1362-9. [PMID: 10336527].

8. Ola MS, Moore PM, Maddox D, El-Sherbeny A, Huang W, Roon P, Agarwal N, Ganapathy V, Smith SB. Analysis of sigma receptor (σR1) expression in retinal ganglion cells cultured under hyperglycemic conditions and in diabetic mice. Brain Res Mol Brain Res 2002; 107:97-107. [PMID: 12425939].

9. Liu LL, Wang L, Zhong YM, Yang XL. Expression of sigma receptor 1 mRNA and protein in rat retina. Neuroscience 2010; 167:1151-9. [PMID: 20223280].

10. Mavlyutov TA, Nickells RW, Guo LW. Accelerated retinal ganglion cell death in mice deficient in the sigma-1 receptor. Mol Vis 2011; 17:1034-43. [PMID: 21541278].

11. Senda T, Matsuno K, Mita S. The presence of sigma receptor subtypes in bovine retinal membranes. Exp Eye Res 1997; 64:857-60. [PMID: 9249518].

12. Jiang G, Myssona B, Dun Y, Gnana-Prakasam JP, Pbla N, Li W, Dong Z, Ganapathy V, Smith SB. Expression, subcellular localization and regulation of sigma receptor in retinal Müller cells. Invest Ophthalmol Vis Sci 2006; 47:5576-82. [PMID: 17122151].

13. Ha Y, Dun Y, Thangaraju M, Ganapathy V, Smith SB. Sigma receptor 1 modulates ER stress in retinal neurons. Invest Ophthalmol Vis Sci 2011; 52:527-40. [PMID: 20811050].

14. Martin PM, Ola MS, Agarwal N, Ganapathy V, Smith SB. The sigma receptor ligand (+)-pentazocine prevents apoptotic retinal ganglion cell death induced in vitro by homocysteine and glutamate. Brain Res Mol Brain Res 2004; 123:66-75. [PMID: 15046867].

15. Dun Y, Thangaraju M, Prasad P, Ganapathy V, Smith SB. Prevention of excitotoxicity in primary retinal ganglion cells by (+)-pentazocine, a sigma receptor-1 specific ligand. Invest Ophthalmol Vis Sci 2007; 48:4785-94. [PMID: 17989305].

16. Bucolo C, Drago F, Lin LR, Reddy VN. Sigma receptor ligands protect human retinal cells against oxidative stress. Neuroreport 2006; 17:287-91. [PMID: 16462599].

17. Tchedre KT, Huang RQ, Dibas A, Krishnamoorthy RR, Dillion GH, Yorio T. Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction. Invest Ophthalmol Vis Sci 2008; 49:4993-5002. [PMID: 18641291].

18. Zhang XJ, Liu LL, Jiang SX, Zhong YM, Yang XL. Activation of the sigma receptor 1 suppresses NMDA responses in rat retinal ganglion cells. Neuroscience 2011; 177:12-22. [PMID: 21211548].

19. Smith SB, Duplantier J, Dun Y, Myssona B, Roon P, Martin PM, Ganapathy V. In vivo protection against retinal neurodegeneration by the sigma receptor 1 ligand (+)-pentazocine. Invest Ophthalmol Vis Sci 2008; 49:4154-61. [PMID: 18469181].

20. Sabino V, Cottone P, Parylak SL, Stardo L, Zorrilla EP. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res 2009; 198:472-6. [PMID: 19100292].

21. Ha Y, Saul A, Tawfik A, Williams C, Bollinger K, Smith R, Tachikawa M, Zorrilla E, Ganapathy V, Smith SB. Late-onset inner retinal dysfunction in mice lacking sigma receptor 1 (σR1). Invest Ophthalmol Vis Sci 2011; 52:7749-60. [PMID: 21862648].

22. Arden GB, Sivaprasad S. The pathogenesis of early retinal changes of diabetic retinopathy. Doc Ophthalmol 2012; 124:15-26. [PMID: 22302291].

23. Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci 2011; 52:1156-63. [PMID: 21357409].

24. Martin PM, Roon P, Van Ells TK, Ganapathy V, Smith SB. Death of retinal neurons in streptozotocin-induced diabetic
mice. Invest Ophthalmol Vis Sci 2004; 45:3330-6. [PMID: 15326158].

25. Asai R, Nishino T, Matsumura T, Okamoto K, Igarashi K, Pai EF, Nishino T. Two mutations convert mammalian xanthine oxidoreductase to highly superoxide-productive xanthine oxidase. J Biochem 2007; 141:525-34. [PMID: 17301076].

26. Badea TC, Nathans J. Morphologies of mouse retinal ganglion cells expressing transcription factors Brn3a, Brn3b, and Brn3c: analysis of wild type and mutant cells using genetically-directed sparse labeling. Vision Res 2011; 51:269-79. [PMID: 20826176].

27. Savinova OV, Sugiyama F, Martin JE, Tomarev SI, Paigen BJ, Smith RS, John SWM. Intraocular pressure in genetically distinct mice: an update and strain survey. BMC Genet 2001; 2:12-[PMID: 11532192].

28. Sieving PA, Frishman LJ, Steinberg RH. Scotopic threshold response of proximal retina in cat. J Neurophysiol 1986; 56:1049-61. [PMID: 3783228].

29. Saszik SM, Robson JG, Frishman LJ. The scotopic threshold response of the dark-adapted electroretinogram of the mouse. J Physiol 2002; 543:899-916. [PMID: 12231647].

30. McCann DJ, Weissman AD, Su TP. Sigma-1 and sigma-2 sites in rat brain: comparison of regional, ontogenetic, and subcellular patterns. Synapse 1994; 17:182-9. [PMID: 7974201].

31. Cobos EJ, Entrena JM, Nieto FR, Cendan CM, Del Pozo E. Pharmacology and therapeutic potential of sigma [1] receptor ligands. Curr Neuropharmacol 2008; 6:344-66. [PMID: 19587856].

32. Du Y, Miller CM, Kern TS. Hyperglycemia increases mitochondrial superoxide in retina and retinal cells. Free Radic Biol Med 2003; 35:1491-9. [PMID: 14642397].

33. Arden GB, Sivaprasad S. Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr Diabetes Rev 2011; 7:291-304. [PMID: 21916837].

34. Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des 2008; 14:962-8. [PMID: 18473846].

35. Kowluru RA, Kanwar M. Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2. Free Radic Biol Med 2009; 46:1677-85. [PMID: 19345729].

36. Desco MC, Asensi M, Márquez R, Martínez-Valls J, Vento M, Pallardó FV, Sastre J, Viña J. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002; 51:1118-24. [PMID: 11916934].

37. Tchedre KT, Yorio T. Sigma-1 receptors protect RGC-5 cells from apoptosis by regulating intracellular calcium, Bax levels, and caspase-3 activation. Invest Ophthalmol Vis Sci 2008; 49:2577-88. [PMID: 18296662].

38. Bucolo C, Campana G, Di Toro R, Cacciaguerra S, Spampinato S. Sigma1 recognition sites in rabbit iris-ciliary body: topical sigma-site agonists lower intraocular pressure. J Pharmacol Exp Ther 1999; 289:1362-9. [PMID: 10336527].

Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. The print version of this article was created on 30 November 2012. This reflects all typographical corrections and errata to the article through that date. Details of any changes may be found in the online version of the article.